Biotechnology Companies By Roa

Return On Asset
ROAEfficiencyMarket RiskExp Return
1MEIP MEI Pharma
0.2
(0.05)
 2.42 
(0.11)
2PTGX Protagonist Therapeutics
0.2
(0.03)
 2.69 
(0.07)
3ADMA ADMA Biologics
0.2
 0.04 
 4.52 
 0.18 
4MDXG MiMedx Group
0.18
 0.18 
 4.17 
 0.75 
5CPRX Catalyst Pharmaceuticals
0.18
 0.09 
 1.97 
 0.17 
6HALO Halozyme Therapeutics
0.15
(0.07)
 3.75 
(0.26)
7IRWD Ironwood Pharmaceuticals
0.13
(0.05)
 4.11 
(0.19)
8KPRX Kiora Pharmaceuticals
0.13
 0.02 
 3.81 
 0.09 
9EXEL Exelixis
0.13
 0.24 
 2.39 
 0.57 
10VRTX Vertex Pharmaceuticals
0.12
(0.01)
 1.68 
(0.02)
11GILD Gilead Sciences
0.12
 0.20 
 1.45 
 0.28 
12UTHR United Therapeutics
0.12
 0.07 
 1.69 
 0.13 
13NBIX Neurocrine Biosciences
0.12
 0.05 
 1.65 
 0.09 
14THTX Theratechnologies
0.12
 0.11 
 3.46 
 0.37 
15INDV Indivior PLC Ordinary
0.11
 0.07 
 3.93 
 0.26 
16GMAB Genmab AS
0.11
(0.22)
 1.54 
(0.34)
17SPRO Spero Therapeutics
0.1
(0.09)
 2.49 
(0.23)
18GYRE Gyre Therapeutics
0.1
(0.05)
 4.18 
(0.19)
19PBYI Puma Biotechnology
0.0973
 0.12 
 4.40 
 0.54 
20MNKD MannKind Corp
0.0912
 0.10 
 1.68 
 0.17 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time. Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.